{"product_id":"gilead-pestle-analysis","title":"Gilead Sciences PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGilead Sciences faces a complex external landscape—regulatory scrutiny, shifting drug-pricing debates, advancing biotech technologies, and growing ESG expectations—that could reshape its R\u0026amp;D and market strategies; our PESTLE distills these forces into actionable intelligence. Purchase the full analysis to get detailed risk scenarios, strategic implications, and ready-to-use slides to inform investment or corporate decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation and the Inflation Reduction Act\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ongoing implementation of the Inflation Reduction Act (IRA) is pressuring Gilead’s pricing strategy, as Medicare negotiation could target top antiviral drugs that accounted for roughly $13.5B of revenue in 2024; negotiated price caps may compress gross margins on established products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability and Global Supply Chain Security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrade tensions between the US, EU and China risk disrupting supply of APIs and intermediates; in 2024 global pharma trade volatility rose 12%, increasing procurement costs for firms like Gilead that sourced ~35% of APIs from Asia in 2023. Gilead’s network spans 20+ countries and remains sensitive to shifts in tariffs and export controls that can delay production. Strategic diversification—Gilead expanded capacity with a $500m investment in 2024 to add sites in Ireland and Singapore—mitigates regional political instability risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Funding for HIV and Hepatitis Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic health budgets and programs like PEPFAR (FY2025 US appropriations ~$6.8bn) materially drive demand for Gilead antiviral sales, with PEPFAR and the Global Fund supporting procurement in \u0026gt;50 low- and middle-income countries.\u003c\/p\u003e\n\u003cp\u003eShifts in political leadership or fiscal priorities can cut yearly allocations—PEPFAR funding varied ±5–10% over past decade—creating revenue volatility for Gilead in key markets.\u003c\/p\u003e\n\u003cp\u003eMaintaining access requires sustained advocacy and public-private partnerships; Gilead reported ~$1.2bn in global access investments in 2024 to secure procurement channels and tiered pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Alignment Across International Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical cooperation on healthcare standards accelerates Gilead’s global launch of oncology and inflammation drugs; harmonized approvals cut time-to-market—EMA median approval 426 days vs FDA 303 days (2023), while China’s NMPA reforms reduced review times by ~20% in 2021–2023.\u003c\/p\u003e\n\u003cp\u003eDivergent EU, US, China requirements raise compliance costs—Gilead reported R\u0026amp;D and licensing expenses of $6.2bn in FY2024—risking delayed revenue recognition and market fragmentation.\u003c\/p\u003e\n\u003cp\u003eGilead must align regulatory strategies across jurisdictions through parallel submissions and reliance pathways to optimize rollout and protect peak sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA median approval 303 days (2023) vs EMA 426 days\u003c\/li\u003e\n\u003cli\u003eChina NMPA review times down ~20% (2021–2023)\u003c\/li\u003e\n\u003cli\u003eGilead R\u0026amp;D\/licensing expenses $6.2bn FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaxation Policies and International Profit Repatriation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorporate tax reforms in the US and the OECD two-pillar global minimum tax (15%) affect Gilead’s effective tax rate and cash repatriation strategies; Gilead reported a GAAP tax rate of 12% in 2024 but faces pressure to align with the 15% minimum, which could reduce tax planning opportunities and increase cash tax outflows.\u003c\/p\u003e\n\u003cp\u003eRevisions to IP taxation—shift toward nexus-based and marketing-relief rules—can lower after-tax margins on overseas royalties; in 2024 Gilead booked ~30% of revenue outside the US, so changes materially affect net profitability by region.\u003c\/p\u003e\n\u003cp\u003eFinancial planners must model increased cash taxes and reduced BEPS-driven benefits when valuing Gilead; sensitivity scenarios shifting the effective tax rate by +3–6 percentage points can reduce FCFF and terminal value meaningfully for DCFs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 GAAP tax rate: 12%\u003c\/li\u003e\n\u003cli\u003eOECD global minimum: 15%\u003c\/li\u003e\n\u003cli\u003e~30% revenue from outside US (2024)\u003c\/li\u003e\n\u003cli\u003eValuation sensitivity: +3–6 ppt tax rate → lower FCFF\/terminal value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead faces pricing, tax \u0026amp; supply risks—$13.5B antiviral revenue and margin pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical actions—IRA Medicare negotiation, OECD 15% minimum tax, and trade\/tariff shifts—threaten Gilead’s pricing, margins, and supply chain; IRA targets ~$13.5B antiviral revenue (2024), GAAP tax 12% vs OECD 15%, ~30% revenue outside US, and 35% APIs sourced from Asia (2023). Gilead’s $500m 2024 capacity spend and $1.2bn access investments partially mitigate risks while regulatory divergence raises R\u0026amp;D\/compliance costs ($6.2bn FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntiviral revenue at risk (2024)\u003c\/td\u003e\n\u003ctd\u003e$13.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP tax rate (2024)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD minimum tax\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue outside US (2024)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs from Asia (2023)\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 capacity investment\u003c\/td\u003e\n\u003ctd\u003e$500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 access investments\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/licensing expense (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$6.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Gilead Sciences across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to inform strategy, risk mitigation, and opportunity identification for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE snapshot of Gilead Sciences that highlights regulatory, technological, and market risks for quick inclusion in decks or meeting briefs, with editable notes for regional or pipeline-specific context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Global Interest Rate Environments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent high US Federal Reserve rates (2024 year-end federal funds target 5.25–5.50%) and 10-year Treasury yields around 4.6% increase Gilead Sciences’ cost of debt, raising financing costs for oncology M\u0026amp;A and potentially reducing deal IRRs.\u003c\/p\u003e\n\u003cp\u003eHigher rates make leverage pricier; Gilead’s net debt\/EBITDA (about 1.5x FY2024) and $7–8bn annual cash flow projections shape its ability to fund acquisitions without excessive dilution.\u003c\/p\u003e\n\u003cp\u003eInvestors should monitor credit spreads and Fed guidance, as rate volatility can constrain deal size, push Gilead toward stock-based trades, or delay strategic expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith approximately 45% of 2024 revenue derived outside the US, Gilead faces material exposure to US dollar movements; a 10% dollar appreciation versus major currencies historically reduced reported international revenue by roughly 4–6% in prior periods.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Budget Constraints and Payor Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic downturns and 2024–25 austerity measures have tightened reimbursement: OECD government health spending growth slowed to 1.2% in 2024, prompting stricter payor reviews across Europe and parts of Asia.\u003c\/p\u003e\n\u003cp\u003eInsurers now demand demonstrable long-term value; US private payors rejected or limited access to several high-cost cell therapies in 2024 after cost-effectiveness concerns.\u003c\/p\u003e\n\u003cp\u003eGilead must prove superior cost-effectiveness—health economic models showing lower lifetime costs or QALY gains versus standard care are increasingly required to secure coverage and favorable pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Manufacturing and R\u0026amp;D Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInflation has driven wages for specialized biotech talent up ~6-8% in 2024 and raw-material costs rise ~9% year-over-year, compressing Gilead’s operating margins unless drug prices or efficiency gains offset them.\u003c\/p\u003e\n\u003cp\u003eThe capital-intensive R\u0026amp;D budget is sensitive to inflation; a 5% CPI rise in 2024 can increase pipeline costs by hundreds of millions, affecting future approvals.\u003c\/p\u003e\n\u003cp\u003eOperational efficiency and supply-chain optimization—including hedging energy and sourcing strategies—are essential to protect profitability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized labor +6–8% (2024)\u003c\/li\u003e\n\u003cli\u003eRaw materials +9% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eCPI impact ~5% raises pipeline costs materially\u003c\/li\u003e\n\u003cli\u003eFocus: supply-chain, energy hedging, operational efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Purchasing Power in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising middle classes in markets like India and Brazil—where middle-class consumption grew by ~3% CAGR 2015–2023 and middle-class populations reached ~300m and ~110m respectively in 2024—increase demand for Gilead’s antivirals and HIV treatments but affordability remains constrained.\u003c\/p\u003e\n\u003cp\u003eEconomic volatility, with 2023 GDP growth swings of ±2–4% in many EMs, can suppress uptake of high-cost chronic therapies, pressuring volumes and reimbursement timelines.\u003c\/p\u003e\n\u003cp\u003eTiered pricing and local manufacturing partnerships are essential; Gilead has used differential pricing in ~40+ LMICs and can expand such models to protect margins while boosting access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRising middle class: India ~300m, Brazil ~110m (2024)\u003c\/li\u003e\n\u003cli\u003eEM GDP volatility: ±2–4% swings (2023)\u003c\/li\u003e\n\u003cli\u003eTiered pricing used in 40+ LMICs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh US rates squeeze oncology M\u0026amp;A returns; FX and input inflation pressure growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh US rates (Fed funds 5.25–5.50% end-2024) raise funding costs, pressuring oncology M\u0026amp;A returns; net debt\/EBITDA ~1.5x and $7–8bn annual cash flow guide deal capacity. FX: ~45% revenue ex-US; a 10% USD appreciation cuts reported intl revenue ~4–6%. 2024: specialized labor +6–8%, raw materials +9% YoY; OECD health spending growth 1.2% tightening reimbursement; EM middle class: India ~300m, Brazil ~110m.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10yr US Treasury\u003c\/td\u003e\n\u003ctd\u003e~4.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~1.5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual cash flow\u003c\/td\u003e\n\u003ctd\u003e$7–8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue ex-US\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor inflation\u003c\/td\u003e\n\u003ctd\u003e+6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003e+9% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD health spend growth\u003c\/td\u003e\n\u003ctd\u003e1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia middle class\u003c\/td\u003e\n\u003ctd\u003e~300m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrazil middle class\u003c\/td\u003e\n\u003ctd\u003e~110m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGilead Sciences PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Gilead Sciences PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. It includes the complete political, economic, social, technological, legal, and environmental assessment as displayed. No placeholders or teasers—this is the real, final document you’ll download immediately after payment. The content and structure are identical to the delivered file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751508226425,"sku":"gilead-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gilead-pestle-analysis.png?v=1772232400","url":"https:\/\/matrixbcg.com\/products\/gilead-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}